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PHARMACOECONOMIC RESEARCH
METHODS ISSUES
PPR1
PRE-TEST OF A MARKOV MODEL TO ESTIMATE 
THE COST OF ILLNESS IN AMBULATORY 
PATIENTS: A PRELIMINARY ESTIMATE USING 
PHYSICIAN SURVEY DATA
Halberg DL
University of Arkansas for Medical Sciences, Little Rock, AR, USA
It is known that the therapeutic use of drugs is often a
major contributor to iatrogenic illness. Previous estimates
of society’s cost of drug-induced illness have been esti-
mated to be between $30.1 to $136.8 billion. Therefore,
the cause and prevention of iatrogenic illness is a topic of
great importance and interest to clinicians, educators, ad-
ministrators, and society. Unfortunately, previous studies
have had key disadvantages. First, panels for achieving
necessary probabilities have been limited in scope and
sample size. Second, previous models have not addressed
the recursive nature of health-related events. 
OBJECTIVES: This study had two objectives: 1) to test and
evaluate a questionnaire that will be used in future studies
to assess the probabilities of the various possible outcomes
of drug-related morbidity and mortality (DRMM); 2) to use
this preliminary questionnaire data to produce a cost of ill-
ness model demonstrating the ability of Markov processes
to model health economic questions. 
METHODS: The questionnaire was pre-tested on 22
physicians affiliated with UAMS health center. Of these,
11 (50%) responded to the survey. After revisions were
made to this questionnaire it was mailed to 298 ran-
domly selected physicians in the state of Arkansas. Of
these, 58 usable questionnaires were obtained. Probabili-
ties for the model were compiled based on this data. A
Markov model was constructed using TreeAge Data soft-
ware. Ten possible outcome states were identified for the
model. Monte Carlo simulation was used to establish an
expected value for the cost of illness related to DRMM. 
RESULTS: Extrapolations of the data indicate that the
cost of illness in the United States related to DRMM is
approximately $38 to $52 billion dollars.
PPR2
EVALUATION OF AN EDUCATIONAL 
INTERVENTION ON THE PERCEPTION OF 
COST-EFFECTIVE INFORMATION RELATIVE TO 
CLINICAL INFORMATION
Sarratt D, Cox ER
University of Arizona, College of Pharmacy, Tucson, AZ, USA
How clinical information is presented can affect health-
care providers’ decisions regarding pharmaceuticals. With
the advent of pharmacoeconomic information, it is not
certain how this information may be perceived relative to
clinical data. 
OBJECTIVE: The purpose of this study is to determine the
impact of a 4-week pharmacoeconomic educational inter-
vention on students’ perception of cost-effective claims rel-
ative to clinical information. 
METHODS: A pre-test/post-test design was used to evalu-
ate the impact of an educational intervention on students’
likelihood of recommending the inclusion of an agent on
formulary. Data on the same product were presented using
four different methods: relative (RR) and absolute risk
(AR) reduction, number needed to treat (NNT) and cost-
effectiveness (CE) ratio. The four methods were presented
as four different therapies. Three scenarios were presented.
Students were questioned regarding their knowledge of
and confidence in interpreting cost-effective data as well as
the importance of clinical, safety, CE and cost data in eval-
uating drug therapy. 
RESULTS: Forty-nine third-year PharmD students com-
pleted both pre- and post-tests. How CE claims were per-
ceived relative to clinical information varied across each
of the three scenarios. CE ratio information was ranked
first, second and fourth in terms of the likelihood of rec-
ommending therapy across the three scenarios relative to
clinical data. In two of the three scenarios CE claims
were rated most similar to RR. Significant increases in
knowledge of and confidence in interpreting cost-effec-
tive claims were found (p  0.006). 
CONCLUSION: While overall, students perceive the
value of CE information third in importance to clinical
effectiveness and safety information, the presentation of
CE information does favorably influence the likelihood
of recommending therapy above clinical information.
PPR3
THE ROLE OF PHARMACOECONOMIC 
INVESTIGATIONS IN CREATING THE PATIENT’S 
TREATMENT RECORD
Vorobjev PA, Kobina SA, Vyalkov AI, Semenov VYu, 
Yakimov OS, Novolodskii VM, Belousov YuB
Moscow Medical Academy, Moscow, Russia
Development of the patient’s treatment record is one of the
urgent problems of the current standardization system. The
draft patient’s treatment record has been already drawn up.
Each record has been assumed to be based on a certain pa-
tient’s model—nosological, syndromal, or situation. The
latter are based respectively on a disease, syndrome, or clin-
ical situation. The patient’s model considers the phase and
stage of a disease (or an independent syndrome) and
complications. Additionally are included the terms of the
medical aid (at the outpatient clinic, in hospital, during
transportation) and its purpose (prophylaxis, diagnostics,
treatment, rehabilitation). The model specifies the range of
the simple medical services, manipulations, investigations,
procedures, groups of medical preparations to be pre-
scribed (performed) obligatory when rendering the aid in
the given situation. The model also specifies the auxiliary
range of the investigations, therapeutic manipulations, and
groups of the medicinal preparations. Development of the
222 Abstracts
treatment records should minimize the costs of the medical
aid. However, it is also necessary to consider the cost of
the effect achieved and quality price of not only the medi-
cal aid itself but the life quality to be created as a result of
medical intervention. The latter fact is closely connected
with the ethical and moral aspects of the medical aid. It
predetermines the obligatoriness and the content of the in-
formed patient’s consent to medical intervention that must
be a component of the patient’s treatment record. Using
the results of the pharmacoeconomic investigations and
meta-analysis that must cover not only pharmaceutical fa-
cilities but also the other diagnostic may solve the de-
scribed problems and therapeutic services as well. When
developing such a system, it is necessary to consider the
difficulties that may arise as a result of Russia’s current
practice to widely use the low-informative methods of di-
agnostics, low-efficient medicinal preparations, methods
of physical therapy, and the unavailability of medical in-
formation for the patient.
PPR4
DEVELOPING METHODOLOGICAL 
STANDARDS IN PHARMACOECONOMIC 
RESEARCH: AN APPROACH BY A TASK FORCE 
OF THE AMERICAN COLLEGE OF 
NEUROPSYCHOPHARMACOLOGY
Hirschfeld RMA1, Russell J1, Hylan TR2
1University of Texas Medical Branch, Galveston, TX, USA; 2Eli 
Lilly and Company, Indianapolis, IN, USA (for the ACNP Task 
Force on Development of Methodological Standards in 
Pharmacoeconomic Research)
Pharmacoeconomic studies are increasing in number
along with their use in healthcare decision-making. The
methods and analyses used in these studies are often new
to clinicians; thus, clinicians may often find it difficult to
read, interpret, assess, and use these studies in their own
decision-making when comparing products. 
OBJECTIVE: In late 1997, the American College of Neu-
ropsychopharmacology (ACNP) convened a task force
charged with developing methodological standards that
could be used to evaluate CNS-related (e.g., psychiatric,
neurologic) pharmacoeconomic studies and be used to
rate these studies. 
METHODS: The Task Force was comprised of members
of the ACNP, non-ACNP scientists, and representatives of
the pharmaceutical industry with expertise and interest in
pharmacoeconomics. The Task Force first compiled a draft
set of rating criteria from existing criteria and other guide-
lines for pharmacoeconomic studies. Two separate rounds
of feasibility tests were conducted during which Task
Force members evaluated three pharmacoeconomic studies
using the initial and the revised rating scale. 
RESULTS: To date, a working rating scale using a 6-point
Likert-type responses has been developed which includes
29 aspects of a pharmacoeconomic study over the follow-
ing seven domains: scope of study, study objectives, sam-
ple, methods, definitions, results and discussion, and con-
clusions. The scale is under consideration for use by the
ACNP pending further refinement. 
CONCLUSIONS: A rating scale has been developed by
which to assess pharmacoeconomic studies within a clini-
cal specialty area. Further testing is needed to refine the
scale and assess its psychometric properties.
PPR5
ESTIMATING HEALTHCARE COSTS IN THE 
ABSENCE OF FINANCIAL DATA: A CASE STUDY
Russell MW, Huse DM, Miller JD, Hartz SC
Medical Research International, Burlington, MA, USA
Patient-level healthcare costs are frequently estimated us-
ing claims databases or financial records (e.g., hospital
bills and institutional cost reports). However, in some
healthcare settings, particularly staff model HMOs, this
information is absent. 
OBJECTIVE: To develop a methodology for estimating
costs of healthcare services in the absence of financial
data at a staff-model HMO, using the Asthma Outcomes
Registry as a case study. 
METHODS: The Asthma Outcomes Registry compiled
clinical and economic data on individual asthmatic sub-
jects from three US managed care sites. Two sites pro-
vided data on utilization and cost of healthcare services
derived from health insurance claims. The third site, a
staff-model HMO, provided data on service utilization
but not cost. We used claims data from the two sites that
provided it to impute unit costs of services for treatment
of asthma and allergic rhinitis at the third site. Analysis
of covariance models were fitted to the logarithm of cost
per encounter (or per inpatient day) for patients with
such data, and these models were used to assign a cost
(retransformed logarithm) to each healthcare encounter
at the staff-model HMO. To preserve variation, each en-
counter’s cost was drawn randomly from the distribution
(mean and variance) estimated from the other two sites. 
RESULTS: Estimated geometric mean costs (logarithms 
standard error) of outpatient encounters for asthma and
allergic rhinitis were $78.26 ($4.36  0.014) and $66.02
($4.19  0.032), respectively. Corresponding estimates
for emergency visits and inpatient days for asthma were
$208.51 ($5.34  0.059) and $820.57 ($6.71  0.092).
Visits for allergy testing were estimated to cost $25.03
($3.22  0.009). 
CONCLUSION: Diagnosis-specific unit costs of medical
encounters can be imputed in settings where such data
are absent using data from comparable settings.
PPR6
COST-EFFECTIVENESS ANALYSIS:
A SIMULTANEOUS 
MARGINAL-EFFECT APPROACH
Liu G1, Zhao Z2
1University of Southern California, Los Angeles, CA, USA; 
2Merck-Medco Managed Care, Montvale, NJ, USA
